Allison Bratzel
Stock Analyst at Piper Sandler
(4.76)
# 115
Out of 5,093 analysts
48
Total ratings
71.05%
Success rate
22.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $8.66 | +246.42% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $900.76 | +3.25% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $34.29 | +2.07% | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $81.51 | -5.53% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $96.70 | +5.48% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.75 | +299.10% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $45.25 | +12.71% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $115.05 | -2.65% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $10.73 | +105.13% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $22.80 | +44.74% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $36.45 | +215.50% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.62 | +270.37% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.36 | +211.00% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $43.40 | -47.00% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $20.99 | +4.81% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.29 | +210.08% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.71 | +250.26% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.59 | +457.10% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $8.66
Upside: +246.42%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $900.76
Upside: +3.25%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $34.29
Upside: +2.07%
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $81.51
Upside: -5.53%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $96.70
Upside: +5.48%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.75
Upside: +299.10%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $45.25
Upside: +12.71%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $115.05
Upside: -2.65%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $10.73
Upside: +105.13%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $22.80
Upside: +44.74%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $36.45
Upside: +215.50%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.62
Upside: +270.37%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $8.36
Upside: +211.00%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $43.40
Upside: -47.00%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $20.99
Upside: +4.81%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.29
Upside: +210.08%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.71
Upside: +250.26%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.59
Upside: +457.10%